• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝癌干细胞的分离及其鉴定进展。

Advances in Liver Cancer Stem Cell Isolation and their Characterization.

机构信息

Centre for Pharmacology and Toxicology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

出版信息

Stem Cell Rev Rep. 2021 Aug;17(4):1215-1238. doi: 10.1007/s12015-020-10114-6. Epub 2021 Jan 11.

DOI:10.1007/s12015-020-10114-6
PMID:33432485
Abstract

Over the last decade research on cancer stem cells (CSC) significantly contributed to a better understanding of tumor biology. Given their similarity to normal stem cells, i.e. self-renewal and pluripotency the need arises to develop robust protocols for the isolation and characterization of CSCs. As with other malignancies, hepatic tumors are composed of a heterogeneous population of cells including liver cancer stem cells (LCSC). Yet, a precise understanding of why stem cells become cancerous is still lacking. There is unmet need to develop robust protocols for the successful isolation of LCSCs from human tissue resection material as to assist in the development of molecular targeted therapies. Here we review the research progress made in the isolation and characterization of LCSCs by considering a wide range of cell surface markers and sorting methods, as applied to side populations, microsphere cultures and the gradient centrifugation method. We emphasize the different fluorescence activated cell sorting methods and the possibility to enrich LCSCs by immunomagnetic beads. We review the specificity of functional assays by considering ABCG transporter and ALDH1 enzyme activities and evaluate the in vivo tumorigenicity of LCSCs in highly sensitive bioassays. Finally, we evaluate different LCSC markers in association with viral and non-viral liver disease and explore the potential of novel drug delivery systems targeting CD133, EpCAM, CD13 and CD90 for the development of molecular targeted therapies. Graphical Abstract.

摘要

在过去的十年中,癌症干细胞(CSC)的研究极大地促进了对肿瘤生物学的理解。鉴于它们与正常干细胞的相似性,即自我更新和多能性,因此需要开发用于分离和鉴定 CSC 的稳健方案。与其他恶性肿瘤一样,肝肿瘤由包括肝癌干细胞(LCSC)在内的异质细胞群体组成。然而,对于为什么干细胞会癌变,仍然缺乏确切的认识。因此,迫切需要开发稳健的方案,从人组织切除材料中成功分离 LCSC,以协助开发分子靶向疗法。在这里,我们通过考虑广泛的细胞表面标志物和分选方法,综述了 LCSC 的分离和鉴定研究进展,这些方法适用于侧群、微球体培养和梯度离心法。我们强调了不同的荧光激活细胞分选方法和通过免疫磁珠富集 LCSC 的可能性。我们通过考虑 ABCG 转运蛋白和 ALDH1 酶活性来评估功能测定的特异性,并在高度敏感的生物测定中评估 LCSC 的体内致瘤性。最后,我们评估了与病毒和非病毒肝病相关的不同 LCSC 标志物,并探索了针对 CD133、EpCAM、CD13 和 CD90 的新型药物输送系统靶向 LCSC 的潜力,以开发分子靶向疗法。

相似文献

1
Advances in Liver Cancer Stem Cell Isolation and their Characterization.肝癌干细胞的分离及其鉴定进展。
Stem Cell Rev Rep. 2021 Aug;17(4):1215-1238. doi: 10.1007/s12015-020-10114-6. Epub 2021 Jan 11.
2
The power and the promise of liver cancer stem cell markers.肝癌干细胞标志物的威力与前景。
Stem Cells Dev. 2011 Dec;20(12):2023-30. doi: 10.1089/scd.2011.0012. Epub 2011 Aug 4.
3
Research progress and prospects of markers for liver cancer stem cells.肝癌干细胞标志物的研究进展与展望
World J Gastroenterol. 2015 Nov 14;21(42):12190-6. doi: 10.3748/wjg.v21.i42.12190.
4
Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells.利用癌症干细胞标志物分离和鉴定肝癌干细胞的功效。
Stem Cells Dev. 2013 Oct 1;22(19):2655-64. doi: 10.1089/scd.2012.0703. Epub 2013 Jun 8.
5
8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin.8-溴-7-甲氧基白杨素通过下调β-连环蛋白抑制肝癌干细胞特性。
World J Gastroenterol. 2013;19(43):7680-95. doi: 10.3748/wjg.v19.i43.7680.
6
Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies.肝癌中癌症干细胞的功能与综合治疗策略。
Cells. 2020 May 26;9(6):1331. doi: 10.3390/cells9061331.
7
The effects and mechanisms of SLC34A2 on tumorigenicity in human non-small cell lung cancer stem cells.SLC34A2对人非小细胞肺癌干细胞致瘤性的影响及机制
Tumour Biol. 2016 Aug;37(8):10383-92. doi: 10.1007/s13277-016-4928-y. Epub 2016 Feb 4.
8
A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM/CD133 nonStem Cells into EpCAM/CD133 Liver Cancer Stem Cells in HCC Cell Line HuH7.KLF4 在调控 EpCAM/CD133 非干细胞向 HCC 细胞系 HuH7 中的 EpCAM/CD133 肝癌干细胞去分化中的新功能。
Cells. 2020 May 12;9(5):1198. doi: 10.3390/cells9051198.
9
Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells.肝癌细胞系的侧群细胞比例随肿瘤去分化而增加,但缺乏癌症干细胞的特征。
J Gastroenterol Hepatol. 2014 May;29(5):1092-101. doi: 10.1111/jgh.12484.
10
Detection of ALDH1 activity in rabbit hepatic VX2 tumors and isolation of ALDH1 positive cancer stem cells.兔肝VX2肿瘤中ALDH1活性的检测及ALDH1阳性癌症干细胞的分离。
J Transl Med. 2016 Feb 12;14:49. doi: 10.1186/s12967-016-0785-0.

引用本文的文献

1
Circular RNAs in cancer stem cells: Insights into their roles and mechanisms (Review).癌症干细胞中的环状RNA:对其作用和机制的见解(综述)
Int J Mol Med. 2025 Mar;55(3). doi: 10.3892/ijmm.2025.5491. Epub 2025 Jan 24.
2
MicroRNA Profiling of PRELI-Modulated Exosomes and Effects on Hepatic Cancer Stem Cells.PRELI 调控的外泌体的微小 RNA 谱分析及其对肝癌干细胞的影响。
Int J Mol Sci. 2024 Dec 11;25(24):13299. doi: 10.3390/ijms252413299.
3
Targeting Hepatic Cancer Stem Cells (CSCs) and Related Drug Resistance by Small Interfering RNA (siRNA).

本文引用的文献

1
Knockdown of STIP1 inhibits the invasion of CD133‑positive cancer stem‑like cells of the osteosarcoma MG63 cell line via the PI3K/Akt and ERK1/2 pathways.敲低 STIP1 通过 PI3K/Akt 和 ERK1/2 通路抑制骨肉瘤 MG63 细胞系中 CD133阳性肿瘤干细胞样细胞的侵袭。
Int J Mol Med. 2020 Dec;46(6):2251-2259. doi: 10.3892/ijmm.2020.4764. Epub 2020 Oct 21.
2
Cyclodextrin-mediated formation of porous RNA nanospheres and their application in synergistic targeted therapeutics of hepatocellular carcinoma.环糊精介导的多孔RNA纳米球的形成及其在肝细胞癌协同靶向治疗中的应用。
Biomaterials. 2020 Dec;261:120304. doi: 10.1016/j.biomaterials.2020.120304. Epub 2020 Aug 7.
3
利用小干扰RNA(siRNA)靶向肝癌干细胞(CSCs)及相关耐药性
Cell Biochem Biophys. 2024 Dec;82(4):3031-3051. doi: 10.1007/s12013-024-01423-5. Epub 2024 Jul 26.
4
Cancer stem cells: advances in knowledge and implications for cancer therapy.癌症干细胞:知识进展及其对癌症治疗的影响。
Signal Transduct Target Ther. 2024 Jul 5;9(1):170. doi: 10.1038/s41392-024-01851-y.
5
Cancer Stem Cells from Definition to Detection and Targeted Drugs.从定义到检测与靶向药物的癌症干细胞
Int J Mol Sci. 2024 Mar 31;25(7):3903. doi: 10.3390/ijms25073903.
6
Colorectal Cancer Stem Cells and Targeted Agents.结直肠癌干细胞与靶向药物
Pharmaceutics. 2023 Dec 12;15(12):2763. doi: 10.3390/pharmaceutics15122763.
7
Targeting the mechano-microenvironment and liver cancer stem cells: a promising therapeutic strategy for liver cancer.靶向机械微环境和肝癌干细胞:肝癌有前途的治疗策略。
Cancer Biol Med. 2023 Nov 24;20(11):816-29. doi: 10.20892/j.issn.2095-3941.2023.0229.
8
Stem cell therapy for hepatocellular carcinoma and end-stage liver disease.干细胞治疗肝细胞癌和终末期肝病。
J Egypt Natl Canc Inst. 2023 Nov 6;35(1):35. doi: 10.1186/s43046-023-00194-z.
9
Fumagillin regulates stemness and malignancies in cancer stem-like cells derived from liver cancer via targeting to MetAP-2.富马酸二甲酯通过靶向 MetAP-2 调节肝癌来源的肿瘤干细胞干性和恶性肿瘤。
PLoS One. 2023 Jul 28;18(7):e0289024. doi: 10.1371/journal.pone.0289024. eCollection 2023.
10
Neuronal Vulnerability to Degeneration in Parkinson's Disease and Therapeutic Approaches.帕金森病中神经元易变性与治疗方法。
CNS Neurol Disord Drug Targets. 2024;23(6):715-730. doi: 10.2174/1871527322666230426155432.
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.
在原发性中枢神经系统淋巴瘤中用NGR-hTNF增强R-CHOP的抗肿瘤活性:一项2期试验的最终结果
Blood Adv. 2020 Aug 11;4(15):3648-3658. doi: 10.1182/bloodadvances.2020002270.
4
Cytotoxicity of nonylphenol on spermatogonial stem cells phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin pathway.壬基酚对精原干细胞磷脂酰肌醇-3激酶/蛋白激酶B/雷帕霉素哺乳动物靶标通路的细胞毒性。
World J Stem Cells. 2020 Jun 26;12(6):500-513. doi: 10.4252/wjsc.v12.i6.500.
5
Immune-based therapies for hepatocellular carcinoma.基于免疫的肝细胞癌治疗方法。
Oncogene. 2020 Apr;39(18):3620-3637. doi: 10.1038/s41388-020-1249-9. Epub 2020 Mar 10.
6
ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation.ZHX2 通过 KDM2A 介导的 H3K36 去甲基化抑制肝癌干细胞样特性。
EBioMedicine. 2020 Mar;53:102676. doi: 10.1016/j.ebiom.2020.102676. Epub 2020 Feb 27.
7
Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma.在肝细胞癌中,抑制EZH2通过Notch1相关的微小RNA靶向Notch1激活依赖性肝癌干细胞来减弱索拉非尼耐药性。
Transl Oncol. 2020 Mar;13(3):100741. doi: 10.1016/j.tranon.2020.01.002. Epub 2020 Feb 22.
8
Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.嵌合抗原受体 T 细胞疗法治疗急性淋巴细胞白血病。
Curr Treat Options Oncol. 2020 Feb 5;21(2):16. doi: 10.1007/s11864-020-0706-6.
9
Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma.外放射状胶质样癌症干细胞有助于胶质母细胞瘤的异质性。
Cell Stem Cell. 2020 Jan 2;26(1):48-63.e6. doi: 10.1016/j.stem.2019.11.015.
10
Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.嵌合抗原受体 T 细胞疗法治疗难治/复发性多发性骨髓瘤的最新进展。
J Zhejiang Univ Sci B. 2020;21(1):29-41. doi: 10.1631/jzus.B1900351.